Trial Profile
C-PATROL - a Single Arm, Prospective Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms C-PATROL
- Sponsors AstraZeneca
- 24 Oct 2023 Final survival results presented at the 48th European Society for Medical Oncology Congress.
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Quality of life interim results presented at the 45th European Society for Medical Oncology Congress